60 Degrees Pharmaceuticals Shareholders Greenlight Reverse Split and Equity Plan Expansion

summarizeSummary

At the annual meeting on August 5, 2026, shareholders of 60 Degrees Pharmaceuticals approved a reverse stock split (1:5 to 1:10), an 800,000-share increase to the equity incentive plan, and other proposals.

check_boxKey Events · Corporate Governance and Compliance · SXTP

• Reverse Stock Split Approved

  Shareholders approved a reverse stock split at a ratio between 1:5 and 1:10, with the board authorized to determine the exact ratio. This is the second reverse split in two years, aimed at maintaining Nasdaq listing compliance.

• Equity Incentive Plan Increase

  An amendment to the 2022 Equity Incentive Plan was approved, increasing the share reserve by 800,000 shares. This adds potential dilution but provides flexibility for employee retention and capital raising.

• Management Success Fee Approved

  A success fee of 5% of deal proceeds between $40M and $100M, and 6% above $100M, was approved for management in the event of a change of control or sale of Arakoda, aligning incentives for a strategic transaction.

• Director Elections and Auditor Ratification

  All five director nominees were elected, and RBSM LLP was ratified as the independent auditor for fiscal year 2026.

auto_awesomeAnalysis · SXTP · Life Sciences

At the annual meeting, shareholders approved all proposals, including a second reverse stock split at a ratio between 1:5 and 1:10 and an 800,000-share increase to the equity incentive plan. The reverse split, which gives the board discretion to set the exact ratio, is a critical move to maintain Nasdaq listing compliance amid severe cash constraints and a going-concern warning. While the equity plan increase introduces potential dilution, it also provides a necessary tool for retaining talent and raising capital. Additionally, a success fee for management in the event of a change of control or sale of Arakoda was approved, aligning incentives for a potential strategic transaction. These approvals follow a period of severe cash constraints and a going-concern warning, making the reverse split a critical step to avoid delisting and the equity plan a necessary but dilutive measure.